SG3 Management’s Avita Medical RCEL Stock Holding History

SG3 Management’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-23,500	Closed	-$124K	–	310
2022 Q3	$124K	Hold	23,500	–	–	0.02%	219
2022 Q2	$112K	Hold	23,500	–	–	0.01%	315
2022 Q1	$199K	Buy	+23,500	New	+$217K	0.01%	766

Other funds holding RCEL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

SG3 Management's RCEL Position: Q4 2022 in Review

SG3 Management sold out of Avita Medical (RCEL) in Q4 2022, closing a stake of 29,650 shares — an estimated $156K sold.

SG3 Management first reported a position in RCEL in Q1 2022 and held it in 3 quarters. The position peaked at $156K in Q3 2022. 52 funds tracked by Wall St. Rank hold RCEL as of Q4 2022.

SG3 Management reported no remaining Avita Medical position as of Q4 2022 after selling out during the quarter.
SG3 Management sold 29,650 Avita Medical shares in Q4 2022, an estimated $156K.
SG3 Management first reported a position in Avita Medical in Q1 2022 and held it in 3 quarters.
SG3 Management's Avita Medical position peaked at $156K in Q3 2022.
52 funds tracked by Wall St. Rank held Avita Medical as of Q4 2022.

Based on SG3 Management's 13F filing for Q4 2022, filed 14 Feb 2023.